Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reem Karmali

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
Molecular and Clinical Oncology|April 18, 2017
Phase 2 study of CHOP-R-14 followed by <sup>90</sup>Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphomaReem Karmali, Melissa L Larson, Jamile M Shammo, et al.
Molecular and Clinical Oncology|April 18, 2017
Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literatureKristin Richardson, Taha Alrifai, Kelly Grant-Szymanski, et al.
Leukemia & Lymphoma|March 5, 2015
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemiaReem Karmali, Melissa L Larson, Jamile M Shammo, et al.
British Journal of Haematology|April 4, 2019
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphomaMadelyn Burkart, Michael Schieber, Sanjib Basu, et al.
American Journal of Physical Medicine & Rehabilitation|May 21, 2025
Inpatient Rehabilitation Outcomes of Cancer Patients After Chimeric Antigen Receptor T-cell TherapyEric W Villanueva, Christopher W Lewis, Kathryn Abplanalp, et al.
Oncotarget|February 1, 2018
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agentsReem Karmali, Vineela Chukkapalli, Leo I Gordon, et al.
Journal of Lower Genital Tract Disease|December 23, 2017
Painless Vulvar Masses as Initial Manifestation of Marginal Zone LymphomaMargaux J Kanis, Molly Zielenbach, Reem Karmali, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 18, 2020
Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphomaAdam Yuh Lin, Jonathan Scott Rink, Reem Karmali, et al.
Blood Reviews|December 1, 2014
All in the family: Clueing into the link between metabolic syndrome and hematologic malignanciesReem Karmali, Andrew Dalovisio, Jeffrey A Borgia, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2011
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphomaReem Karmali, Mohamad Kassar, Parameswaran Venugopal, et al.
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
Molecular and Clinical Oncology|April 18, 2017
Phase 2 study of CHOP-R-14 followed by <sup>90</sup>Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphomaReem Karmali, Melissa L Larson, Jamile M Shammo, et al.
Molecular and Clinical Oncology|April 18, 2017
Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literatureKristin Richardson, Taha Alrifai, Kelly Grant-Szymanski, et al.
Leukemia & Lymphoma|March 5, 2015
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemiaReem Karmali, Melissa L Larson, Jamile M Shammo, et al.
British Journal of Haematology|April 4, 2019
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphomaMadelyn Burkart, Michael Schieber, Sanjib Basu, et al.
American Journal of Physical Medicine & Rehabilitation|May 21, 2025
Inpatient Rehabilitation Outcomes of Cancer Patients After Chimeric Antigen Receptor T-cell TherapyEric W Villanueva, Christopher W Lewis, Kathryn Abplanalp, et al.
Oncotarget|February 1, 2018
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agentsReem Karmali, Vineela Chukkapalli, Leo I Gordon, et al.
Journal of Lower Genital Tract Disease|December 23, 2017
Painless Vulvar Masses as Initial Manifestation of Marginal Zone LymphomaMargaux J Kanis, Molly Zielenbach, Reem Karmali, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 18, 2020
Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphomaAdam Yuh Lin, Jonathan Scott Rink, Reem Karmali, et al.
Blood Reviews|December 1, 2014
All in the family: Clueing into the link between metabolic syndrome and hematologic malignanciesReem Karmali, Andrew Dalovisio, Jeffrey A Borgia, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2011
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphomaReem Karmali, Mohamad Kassar, Parameswaran Venugopal, et al.
Pageof 14